|
COX-2 Inhibitors Information
COX-2 Inhibitors which cover Vioxx® (rofecoxib), Bextra® (valdecoxib) and Celebrex® are not particularly up to the mark. After a vast clinical study and research by the group of scientists, it is clear that this medication can cause a number of physical and psychological disorders in patients. COX-2 inhibitors belong to NSAID class and these medications were basically applied to remove the arthritis and pain in the muscle. But according to the doctors, COX-2 inhibitors are loaded with many dangerous and risky side effects which decrease the value of these medications.
For this particular reason, in 2004, Merck and Co pulled this medication from the American market due to its negative impact. COX-2 inhibitors brighten the risk of occurrence of heart attack, blood clotting and stroke to the patients. There is another minus point of this type of COX-2 inhibitor. People will run the risk of life being affected by thromboembolic disease due to consumption of that type of medication. According to Patricia McGettigan, MD in unison with David Henry, another well-known doctor researching in the University of Newcastle in Australia has published two important and most popular reviews in which they have commented regarding the close proximity between the risk of the cardiovascular disease and the intake of COX-2 inhibitors. The fact is that they have proved very clearly that there is higher chance of the steady hike in the onset of cardiovascular disease through the consumption of meloxicam and rofecoxib.
On the other hand, Zhang, a well known researcher and doctor in Harvard School of Public Health in Boston, has opined that COX-2 inhibitors enhance the risk of the attack of renal and proarrhythmic problems. A survey on 116094 patients has confirmed the close relation between the Vioxx and the peripheral edema, hypertension and the loss of renal functionality. Patients therefore must avoid taking these medications for the betterment of the health. However, the scientists are confidant that the risks of kidney related disorders and arrhythmias have not been traced after the intake of other COX-2 inhibitors like celecoxib and Etoricoxib. After consuming rofecoxib, patients will be under the danger of being infected by ventricular fibrillation, cardiac death and other arrhythmic episodes. Therefore, if a person dies or being seriously affected by the cardiovascular diseases after the daily consumption of these COX-2 inhibitors, he can file lawsuits in the court against the drug manufacturer or the seller. The compensation will be high in this case. To register the case against the accused company or person, there is the requirement of the intelligent lawyer who is very competent and experienced.
|
|
Bextra® was withdrawn by Pfizer on April 7, 2005 due to the drug’
s side effects including heart attack, stroke, blood clots, and skin
disorders such as Stevens Johnson Syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN).
Celebrex® is the only COX-2 inhibitor that remains on the market.
Many doctors and patients have criticized Merck, Pfizer and the
FDA for allowing Vioxx®, Bextra® and Celebrex® to remain on the
market for years following their approval despite numerous early
findings of serious and potentially fatal cardiovascular risks and
skin disorders.
|
